Peloton Wealth Strategists Has $1.31 Million Position in Danaher Co. (NYSE:DHR)

Peloton Wealth Strategists boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 3.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,696 shares of the conglomerate’s stock after buying an additional 190 shares during the period. Peloton Wealth Strategists’ holdings in Danaher were worth $1,308,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Heck Capital Advisors LLC acquired a new stake in Danaher during the fourth quarter worth $27,000. Decker Retirement Planning Inc. bought a new position in shares of Danaher during the fourth quarter valued at $31,000. Golden State Wealth Management LLC bought a new position in shares of Danaher during the fourth quarter valued at $31,000. Strategic Financial Concepts LLC bought a new position in shares of Danaher during the fourth quarter valued at $31,000. Finally, Pineridge Advisors LLC lifted its holdings in shares of Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after acquiring an additional 57 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Danaher stock opened at $205.69 on Friday. The firm has a market capitalization of $147.01 billion, a P/E ratio of 38.96, a PEG ratio of 2.66 and a beta of 0.83. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The business has a 50-day moving average of $225.00 and a 200-day moving average of $245.50. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the firm posted $2.09 earnings per share. On average, equities analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.32 dividend. The ex-dividend date of this dividend is Friday, March 28th. This is a positive change from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. Danaher’s payout ratio is currently 24.24%.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Royal Bank of Canada reissued an “outperform” rating and set a $277.00 price objective (down from $299.00) on shares of Danaher in a report on Thursday, January 30th. Robert W. Baird cut their price target on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company cut their price target on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Guggenheim assumed coverage on Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target for the company. Finally, Jefferies Financial Group cut their price target on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.